The estimated Net Worth of Karin Eastham is at least $148 Million dollars as of 1 April 2024. Ms. Eastham owns over 10,000 units of Nektar Therapeutics stock worth over $64,688 and over the last 20 years she sold NKTR stock worth over $147,330,193. In addition, she makes $352,728 as Independent Director at Nektar Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Eastham NKTR stock SEC Form 4 insiders trading
Karin has made over 31 trades of the Nektar Therapeutics stock since 2008, according to the Form 4 filled with the SEC. Most recently she exercised 10,000 units of NKTR stock worth $131,900 on 1 April 2024.
The largest trade she's ever made was exercising 35,000 units of Nektar Therapeutics stock on 13 January 2023 worth over $38,500. On average, Karin trades about 3,329 units every 62 days since 2004. As of 1 April 2024 she still owns at least 43,125 units of Nektar Therapeutics stock.
You can see the complete history of Ms. Eastham stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Karin Eastham biography
Karin Eastham serves as Independent Director of the Company. Ms. Eastham currently serves on the boards of directors of several life sciences companies. Ms. Eastham has served on the board of directors of Geron Corporation since March 2009, Veracyte, Inc. since December 2012, and Personalis, Inc. since November 2019. Ms. Eastham served as a member of the board of directors of Ilumina Inc. from August 2004 to May 2019, MorphoSys AG from May 2012 to May 2017, Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012, Genoptix, Inc. from July 2008 until its acquisition in March 2011, Tercica, Inc. from December 2003 until its acquisition in October 2008, and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. From May 2004 to September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research (now Sanford Burnham Prebys Medical Discovery Institute), a non-profit corporation engaged in biomedical research. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. Ms. Eastham previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant.
What is the salary of Karin Eastham?
As the Independent Director of Nektar Therapeutics, the total compensation of Karin Eastham at Nektar Therapeutics is $352,728. There are 14 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
How old is Karin Eastham?
Karin Eastham is 70, she's been the Independent Director of Nektar Therapeutics since 2018. There are 1 older and 17 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Insiders trading at Nektar Therapeutics
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,397,380 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $45,254. The most recent stock trade was executed by Jonathan Zalevsky on 20 February 2024, trading 9,014 units of NKTR stock currently worth $6,130.
What does Nektar Therapeutics do?
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
What does Nektar Therapeutics's logo look like?
Complete history of Ms. Eastham stock trades at Geron, Illumina Inc, Nektar Therapeutics, Veracyte Inc, and Personalis Inc
Nektar Therapeutics executives and stock owners
Nektar Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Zalevsky,
Chief Research and Development Officer -
Howard Robin,
President, Chief Executive Officer, Director -
Gilbert Labrucherie,
Chief Financial Officer, Chief Operating Officer, Senior Vice President -
John Northcott,
Senior Vice President and Chief Commercial Officer -
Howard W. Robin,
CEO, Pres & Director -
Jillian Thomsen,
Senior Vice President - Finance, Chief Accounting Officer -
Gilbert M. Labrucherie J.D.,
Sr. VP, CFO & COO -
Dr. Jonathan Zalevsky,
Chief R&D Officer -
John P. Northcott,
Sr. VP & Chief Commercial Officer -
Mark A. Wilson,
Sr. VP, Gen. Counsel & Sec. -
Myriam Curet,
Independent Director -
Robert Chess,
Independent Chairman of the Board -
Roy Whitfield,
Lead Independent Director -
R. Scott Greer,
Independent Director -
Karin Eastham,
Independent Director -
Jeff Ajer,
Independent Director -
Dr. Brian L. Kotzin,
Sr. VP of Clinical Devel. & Head of Immunology -
Dr. Mary Tagliaferri L.Ac., M.D.,
Sr. VP & Exec. Clinical Fellow -
Jennifer Ruddock,
Sr. VP of Strategy & Corp. Affairs -
Robert Bacci,
Sr. VP of HR and Facilities -
Jillian B. Thomsen,
Sr. VP of Fin. & Chief Accounting Officer -
Lutz Lingnau,
Director -
Dennis L Winger,
Director -
Ivan P. Gergel,
SVP Drug Development & CMO -
Maninder Hora,
SVP Pharma Dev and Mfg -
Christopher A Kuebler,
Director -
Joseph J Krivulka,
Director -
Melvin Perelman,
Director -
Ajit Gill,
CEO & President -
Randall W Moreadith,
SVP Drug Development -
Bharat M Chowrira,
COO & Head of PEGylation BU -
Robert Medve,
Chief Medical Officer -
Nevan C Elam,
General Counsel and Secretary -
Timothy Harkness,
SVP & Chief Financial Officer -
John Stuart Patton,
Chief Scientific Officer -
Irwin Lerner,
Director -
Michael A/Ca Brown,
Director -
Masuoka K. Lorianne,
SVP & Chief Medical Officer -
Susan Wang,
Director -
Rinko Ghosh,
SVP & Chief Business Officer -
David Johnston,
SVP, Research & Development -
Ajay Bansal,
CFO, VP Finance & Admin -
Hoyoung Huh,
Chief Operating Officer -
J Milton Harris,
President of Nektar AL -
James B Glavin,
Director -
John Nicholson,
SVP & Chief Operating Officer -
Stephen K Doberstein,
SVP & Chief Scientific Officer -
Gil M Labrucherie,
SVP, COO & CFO -
Diana Brainard,
Director -
Mark Andrew Wilson,
Chief Legal Officer